Investor Relations 2021

Key Business Performance ✓ Won approval of EMA in Feb.2021 and will start launching in EU in 2Q21 going forward ✓ Value proposition as the only high-concentration biosimilar with high price competitiveness Market size of Adalimumab in EU 100% 4% 10% 14% 75% EU Adalimumab 50% 45% Market Size $4.0bn 55% ■low-concentration ■high-concentration Note: market size is as of 2020 Source: IQVIA 16% 56% 25% Yuflyma Aiming to launch YuflymaⓇ in more than 70% of the EU Adalimumab market in 2021 '21.2Q(E) 6 countries including Spain (16% among EU Adalimumab market) '21.3Q(E) 7 countries including France, Germany (45%) 3 countries '21.4Q(E) including 0% Italy (11%) HumiraⓇ HyrimozⓇ AmgevitaⓇ ImraldiⓇ Hulio® Note: market size is as of 2020 Source: IQVIA Investor Relations 2021 12

View entire presentation